Jan 19, 2023 09:07 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company

TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's seventh inclusion on the list. Ranked 53rd, Eisai was the highest ranking company among global pharmaceutical companies (please visit here(New Window) for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 6,000 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 25 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai was highly evaluated, particularly in indicators for enhancing employee value such as safe work environment, sick leave support system and employee retention rate.

Eisai's corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
September 05 2024 15:59 JST
 
Eisai Announces Status Relating to Acquisition of Own Shares
September 02 2024 14:12 JST
 
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22 2024 18:54 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
August 14 2024 08:59 JST
 
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
August 06 2024 12:15 JST
 
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 31 2024 12:59 JST
 
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 29 2024 16:59 JST
 
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 25 2024 09:30 JST
 
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 23 2024 19:23 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
 
More Press release >>

Latest Press Release


More Latest Release >>